Member Info for ShrewDEds

Not much activity here, but this is well and truly in the buy zone imo. My amateurish chart has support at this level in a rising channel. Sound fundamentals and technicals, just not well followed.

Prop, learnt to take a bit of profit on the way up but still have some here. Hope all is well with you.

Enjoying the rise here. It wasn't that long ago that equitrder was talking down his own investment and I was one of very few who was extolling its virtues.

Potentially $3m plus a quarter. It all depends on AMYT's commercial abilities though. Aegerion didn't want to continue with the product in the EU market. One would imagine that AMYT will have considerable experience in this area. Set against this there is increasing competition, including PCSK9 inhibitors which cost 5% of Lojuxtin. Looks to me as though there may be some short term income from this deal, once the marketing network has been set up, but income streams may struggle with increasing competition going forwards. Not necessarily transformational in my book, unless AMYT have bigger plans for the product.

No surprise to me that the BoD were busy in the background when all seemed a little quiet. 'Transformational' is always a word that catches the eye. Buys and sells are below the mid price - the real spread is quite reasonable. As with the last RNS, it may take a short while for this news to catch on. I get the feeling that AMYT isn't widely followed.

Amryt secures €20m funding from EIB Amryt Pharma has announced it has secured a €20m debt facility from the European Investment Bank (EIB) on very attractive commercial terms. The facility will not only extend the company's funding until well into 2019, but also provide funding for development of acromegaly product AP102 and potential launch funding for Episalvan in partial thickness wounds. Amryt remains on track to initiate Phase III trials of Episalvan in epidermolysis bullosa (EB) in 1Q17 with results expected in mid-2018 and launch possible in 2019. The EIB funding is non-dilutive and mitigates funding risk. We reiterate our Buy rating and 49p target price. EIB funding. Under the terms of the five-year facility, Amryt can draw down €10m immediately and a further €10m in two equal tranches on achievement of certain milestones. The loan pays an interest rate of 3% p.a. over the Euro LIBOR plus a 10% p.a. interest repayable with the principal. Funded through to 2019. On our revised forecasts, the €20m EIB debt facility will help fund Amryt's operations until well into 2019 by which time Episalvan should have completed Phase III trials in epidermolysis bullosa and be nearing commercialisation. It should also now allow Amryt to launch Episalvan in Europe as a treatment for burns and other partial thickness wounds for which it received EU approval in January 2016. In addition, the debt facility will fund development of orphan drug AP102 in acromegaly, providing funds to complete preclincal development and Phase I trials that are expected to start in 2018. Episalvan in EB is Amryt's key value driver. The drug is due to enter Phase III trials in EB in 1Q17. Development remains on track with results of the 150 patient EB trial expected by mid-2018 and launch possible in 2019. Amryt is now close to finalising a Phase III trial design that would satisfy both EMA and FDA regulatory requirements. It has also finalised selection of a CRO to conduct the trial. With around 55,000 sufferers in the US and Europe, EB represents a significant orphan drug condition with no current treatment other than regular bandaging. We forecast sales of Episalvan in EB of $258m by 2023E with launch in 2019. Reiterate Buy. Based on a hybrid of NPV, comparative and discounted revenue multiple methodologies, we value Amryt at 49p per share, implying significant upside potential to the current share price. Published data suggests Episalvan has significant advantages over current treatment and Zorblisa, Amicus’s competing product in development.

Small mention http://www.dailymail.co.uk/money/markets/article-3995178/MARKET-REPORT-Electronics-firm-Laird-sinks-8-9-taps-investors-185m-bid-pro-actively-address-financial-position.html

Well, if this board is any indicator, sentiment is not good just now. The new facility is massively important though, and represents evidence of the type of funding approach that has previously been put forward by the company. There will no doubt be some more media to follow, which may help.

Having now fully funded our Episalvan program, we will look for further opportunities to fill the incredibly high unmet need in the orphan drugs market." Interesting.

Excellent news I would say. Puts to bed funding questions in the short to medium term. Hopefully the market will agree.

Good job we have a management board in place with a more enlightened perspective.

Do you seriously believe that it is better if the company do not publicise their achievements and potential? Words fail me. For once. TI -from the half yearlies, less than £170k, but how much less I don't know.

As I recall this was always the plan, so it's good to hear it reiterated. Whilst I understand your concerns TI, Wiley has indicated that there are various options to be explored. If you were to look across AIM there won't be many businesses which wouldn't need to consider a fundraise within the next 12 months!

Equi, you sweet talker you. I've no particular knowledge of pharmas and I'm always interested in what others who do have to say. It doesn't mean that I won't challenge though. My approach is that if I'm not happy with the business in which I'm invested then I will sell up and move on. I buy when I think that the price is reasonable, but yes, I often get that bit a little wrong. You won't hear me slating one of my investments though -I wouldn't be invested if I had serious concerns.But despite your concerns about my buy button post (which I stand by) I don't ramp. As for balance, the board does that on it's own without my input. One post of yours, three of mine, and the overall tone will be nicely balanced ;-)

Whilst I'm not arguing with you general point about licencing, there are examples of drugs being licenced out prior to the completion of phase 1 - SAR have one example. I do accept that deals at Phase 2 or later are more usual though.

And looking back you did welcome the news.

I didn't say that a licencing deal is imminent, just that some of the development costs may be met that way. If future phases can be paid for by striking a deal then all to the good. As you will know, orphan designation in itself substantially reduces development costs. Talking of which, you must be delighted that AP102 has achieved FDA orphan status as you previously expressed doubt that it would be achieved.

Care to expand on what aspect of the market they misjudged. Also, as I said yesterday, there is no suggestion that funds will be raised in the near future. The current funding is for the phase 3 development of Episalvan, not for the development of AP102. Only a fool would believe that a small pharma would not need to raise funds to develop products, and I don't believe that you are a fool. However Amryt have indicated that they would look to lower costs by licensing AP102. And are you seriously saying that a pharma sp can not rise because they will need more money at some point in the future.

Rory Nealon interviewed by Justin Waite in podcast 633, talking about reasons to invest in AMYT, potential market size and current valuation.

Anyway, would love to stop and chat, but must dash.